Research ArticleExperimental Studies
PD-L1 Expression and Survival Rates Using TPS and CPS for Nivolumab-treated Head-and-Neck Cancer
TATSUYA ITO, ISAKU OKAMOTO, KUNIHIKO TOKASHIKI, HIROKI SATO, TAKURO OKADA, GAI YAMASHITA, TOSHITAKA NAGAO, HIDEAKI HIRAI, NATSUKI SAIGUSA and KIYOAKI TSUKAHARA
Anticancer Research March 2022, 42 (3) 1547-1554; DOI: https://doi.org/10.21873/anticanres.15628
TATSUYA ITO
1Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan
ISAKU OKAMOTO
1Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan
KUNIHIKO TOKASHIKI
1Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan
HIROKI SATO
1Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan
TAKURO OKADA
1Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan
GAI YAMASHITA
1Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan
TOSHITAKA NAGAO
2Department of Anatomic Pathology, Tokyo Medical University, Tokyo, Japan
HIDEAKI HIRAI
2Department of Anatomic Pathology, Tokyo Medical University, Tokyo, Japan
NATSUKI SAIGUSA
3Department of Pathology, Tokyo Medical University, Tokyo, Japan
KIYOAKI TSUKAHARA
1Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
patientACCESS
patientACCESS - Patients desiring access to articles
In this issue
PD-L1 Expression and Survival Rates Using TPS and CPS for Nivolumab-treated Head-and-Neck Cancer
TATSUYA ITO, ISAKU OKAMOTO, KUNIHIKO TOKASHIKI, HIROKI SATO, TAKURO OKADA, GAI YAMASHITA, TOSHITAKA NAGAO, HIDEAKI HIRAI, NATSUKI SAIGUSA, KIYOAKI TSUKAHARA
Anticancer Research Mar 2022, 42 (3) 1547-1554; DOI: 10.21873/anticanres.15628
PD-L1 Expression and Survival Rates Using TPS and CPS for Nivolumab-treated Head-and-Neck Cancer
TATSUYA ITO, ISAKU OKAMOTO, KUNIHIKO TOKASHIKI, HIROKI SATO, TAKURO OKADA, GAI YAMASHITA, TOSHITAKA NAGAO, HIDEAKI HIRAI, NATSUKI SAIGUSA, KIYOAKI TSUKAHARA
Anticancer Research Mar 2022, 42 (3) 1547-1554; DOI: 10.21873/anticanres.15628
Jump to section
Related Articles
- No related articles found.
Cited By...
- PD-L1 mRNA Detection in Immunohistochemically Negative Patients: A Complementary Method for a Better Treatment Selection?
- Pembrolizumab Monotherapy Versus Pembrolizumab Plus Chemotherapy in Patients With Head and Neck Squamous Cell Carcinoma
- Efficacy of Nivolumab and Pembrolizumab in Platinum-sensitive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Effects of Pembrolizumab in Recurrent/Metastatic Squamous Cell Head and Neck Carcinoma: A Multicenter Retrospective Study
- Nivolumab for Platinum-refractory and -sensitive Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
- Real-world Therapeutic Outcomes of the Pembrolizumab Regimen as First-line Therapy for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Single-center Retrospective Cohort Study in Japan
- Real-world Experience With Pembrolizumab for Advanced-stage Head and Neck Cancer Patients: A Retrospective, Multicenter Study
- Five-year Follow-up of Patients With Head and Neck Cancer Treated With Nivolumab and Long-term Responders for Over Two Years